(RxWiki News) The US Food and Drug Administration has approved a once-a-day medication to treat type 2 diabetes.
That medication is Synjardy XR, which is a combination of two medications: empagliflozin and metformin hydrochloride.
Synjardy XR is available as an extended-release tablet to be taken once a day.
The duo of empagliflozin and metformin hydrochloride was approved in combination with diet and exercise to lower blood sugar in adults with type 2 diabetes.
This medication received approval as a result of multiple clinical trials. Common side effects include nausea, vomiting, diarrhea and gas.
Synjardy XR should not be used in those with type 1 diabetes or diabetic ketoacidosis, a condition in which the blood or urine contains large amounts of ketone.
Serious side effects may occur in some people who take this medication. These include a buildup of lactic acid in the blood called lactic acidosis.
Synjardy XR is marketed by Boehringer Ingelheim and Eli Lilly and Company.
